Skip to main content

Table 2 Patient’s characteristics

From: Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

Parameter CNS metastases as the first site of metastatic disease, N = 108 Non-CNS metastases as the first site of metastatic disease, N = 411 Patients without distant relapse, N = 2641 Overall, N = 3160
Age, median (years) 48.5 48.0 49.0 48.0
cT (n, %)
 cT1–2 61 (57.0) 259 (63.2) 1986 (75.5) 2306 (73.3)
 cT3 15 (14.0) 77 (18.8) 366 (13.9) 458 (14.5)
 cT4a–c 5 (4.7) 26 (6.3) 118 (4.5) 149 (4.7)
 cT4d 26 (24.3) 48 (11.7) 161 (6.1) 235 (7.5)
 Missing 1 1 10 12
cN (n, %)
 cN0 28 (26.2) 159 (39.5) 1394 (53.5) 1581 (50.8)
 cN1 68 (63.6) 209 (51.9) 1100 (42.2) 1377 (44.2)
 cN2 9 (8.4) 23 (5.7) 90 (3.5) 122 (3.9)
 cN3 2 (1.9) 12 (3.0) 20 (0.8) 34 (1.1)
 Missing 1 8 37 46
Breast cancer subtype
 Luminal A-like (grades 1–2) 11 (10.2) 107 (26.2) 836 (31.7) 954 (30.3)
 Luminal B-like (grade 3) 7 (6.5) 61 (14.9) 313 (11.9) 381 (12.1)
 HER2+ 34 (31.5) 76 (18.6) 699 (26.5) 809 (25.7)
 TNBC 56 (51.9) 165 (40.3) 787 (29.9) 1008 (32.0)
 Missing 0 2 6 8
Ki67 index (n, %)
 ≤ 20% 10 (18.5) 58 (28.9) 438 (33.0) 506 (32.0)
 > 20% 44 (81.5) 143 (71.1) 888 (67.0) 1075 (68.0)
 Missing 54 210 1315 1579
Grade (n, %)
 G1 0 (0.0) 10 (2.4) 88 (3.3) 98 (3.1)
 G2 41 (38.0) 186 (45.5) 1305 (49.6) 1532 (48.7)
 G3 67 (62.0) 213 (52.1) 1236 (47.0) 1516 (48.2)
 Missing 0 2 12 14
pCR
 No 92 (85.2) 376 (91.5) 1954 (74.0) 2422 (76.6)
 Yes 16 (14.8) 35 (8.5) 687 (26.0) 738 (23.4)